Skip to main content

Advertisement

SpringerLink
Log in

TGFβ1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFβ1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo-radiotherapy

  • Epidemiology
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The breast cancer incidence has been increasing in the south Indian women. A case (n = 250)–control (n = 500) study was undertaken to investigate the role of Single Nucleotide Polymorphisms (SNP’s) in GSTM1 (Present/Null); GSTP1 (Ile105Val), p53 (Arg72Pro), TGFβ1 (Leu10Pro), c-erbB2 (Ile655Val), and GSTT1 (Null/Present) in breast cancer. In addition, the value of the SNP’s in predicting primary tumor’s pathologic response following neo-adjuvant chemo-radiotherapy was assessed. Genotyping was done using PCR (GSTM1, GSTT1), Taqman Allelic discrimination assay (GSTP1, c-erbB2) and PCR-CTPP (p53 and TGFβ1). None of the gene SNP’s studied were associated with a statistically significant increased risk for the breast cancer. However, combined analysis of the SNP’s showed that p53 (Arg/Arg and Arg/Pro) with TGFβ1 (Pro/Pro and Leu/Pro) were associated with greater than 2 fold increased risk for breast cancer in Univariate (P = 0.01) and Multivariate (P = 0.003) analysis. There was no statistically significant association for the GST family members with the breast cancer risk. TGFβ1 (Pro/Pro) allele was found to predict complete pathologic response in the primary tumour following neo-adjuvant chemo-radiotherapy (OR = 6.53 and 10.53 in Univariate and Multivariate analysis respectively) (P = 0.004) and was independent of stage. This study suggests that SNP’s can help predict breast cancer risk in south Indian women and that TGFβ1 (Pro/Pro) allele is associated with a better pCR in the primary tumour.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Reference

  1. Shanta V, Swaminathan R, Kavitha M (2005) Cancer incidence and mortality in Chennai, India, Year 2002. Madras Metropolitan Tumor Registry, National Cancer Registry Program, Cancer Institute (WIA), Chennai

  2. Samson M, Swaminathan R, Rama R, Sridevi V, Nancy KN, Rajkumar T (2007) Role of GSTM1 (Null/Present), GSTP1 (Ile105Val) and P53 (Arg72Pro) Genetic polymorphisms and the risk of breast cancer - A case control study from south India. Asian Pac J Cancer Prev 8:253–257

    PubMed  Google Scholar 

  3. Wagner TM, Moslinger RA, Muhr D, Langbauer G, Hirtenlehner K et al (1998) BRCA1-related breast cancer in Austrian breast and ovarian cancer families: specific BRCA1 mutations and pathological characteristics. Int J Cancer 77:354–360

    Article  PubMed  CAS  Google Scholar 

  4. Couch FJ, Wang XY, Wu GJ, Qian J, Jenkins RB, James CD (1999) Localization of PS6K to chromosomal region 17q23 and determination of its amplification in breast cancer. Cancer Res 59:1408–1411

    PubMed  CAS  Google Scholar 

  5. Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF (1999) A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 8:843–854

    PubMed  CAS  Google Scholar 

  6. Wang H, Zeng ZC, Bui TA, DiBiase SJ, Qin W, Xia F, Powell SN, Iliakis G et al (2001) Non-homologous end-joining of ionizing radiation-induced DNA double-stranded breaks in human tumor cells deficient in BRCA1 or BRCA21. Cancer Res 61:270–277

    PubMed  CAS  Google Scholar 

  7. Ameyaw MM, Tayeb M, Thornton N, Folayan G, Tariq M, Mobarek A et al (2002) Ethnic variation in the HER-2 codon 655 genetic polymorphism previously associated with breast cancer. J Hum Genet 47:172–175

    Article  PubMed  CAS  Google Scholar 

  8. Dunning AM, Ellis PD, McBride S, Kirschenlohr HL, Healey CS et al (2003) A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 63(10):2610–2615

    PubMed  CAS  Google Scholar 

  9. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D et al (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447:1087–1094

    Article  PubMed  CAS  Google Scholar 

  10. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M et al (2007) A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 39:870–874

    Article  PubMed  CAS  Google Scholar 

  11. Pharoah PD, Tyrer J, Dunning AM, Easton DF, Ponder BA (2007) Association between common variation in 120 candidate genes and breast cancer risk. PLoS Genet 3(3):e42

    Article  PubMed  CAS  Google Scholar 

  12. Lee KM, Park SK, Hamajima N, Tajima K, Yoo KY, Shin A et al (2005) Genetic polymorphisms of TGFβ11 & TNF-β and breast cancer risk. Breast Cancer Res Treat 90:149–155

    Article  PubMed  CAS  Google Scholar 

  13. Krajinovic M, Labuda D, Richer C, Karimi S, Sinnett D (1999) A susceptibility to childhood acute lymphoblastic leukemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. Blood 93:1496–1501

    PubMed  CAS  Google Scholar 

  14. Beslow NE, Day NE (1980) Statistical methods in cancer research. Vol I. The analysis of cases-control studies. IARC Scientific Publications No 32, IARC, Lyon

    Google Scholar 

  15. Kaplan EL, Meier P (1958) Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457–481

    Article  Google Scholar 

  16. Cox A, Dunning AM, Garcia-Closas M, Balasubramanian S, Reed MW, Pooley KA, Scollen S et al (2007) A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 39(5):688

    Article  CAS  Google Scholar 

  17. Xie D, Shu XO, Deng Z, Wen WQ, Creek KE, Dai Q et al (2000) Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 92:412–417

    Article  PubMed  CAS  Google Scholar 

  18. Pinto D, Vasconcelos A, Costa S, Pereira D, Rodrigues H et al (2004) HER2 polymorphism and breast cancer risk in Portugal. Eur J Cancer Prev 13:177–181

    Article  PubMed  CAS  Google Scholar 

  19. Tommasi S, Fedele V, Lacalamita R, Bruno M, Schittulli F, Ginzinger D et al (2007) 655Val and 1170Pro ERBB2 SNPs in familial breast cancer risk and BRCA1 alterations. Cell Oncol 29:241–248

    PubMed  CAS  Google Scholar 

  20. Benusiglio PR, Lesueur F, Luccarini C, Conroy DM, Shah M et al (2005) Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case-control study. Breast Cancer Res 7:204–209

    Article  CAS  Google Scholar 

  21. Han W, Kang D, Lee JE, Park IA, Choi JY, Lee KM et al (2005) A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea. Clin Cancer Res 11:4775–4778

    Article  PubMed  CAS  Google Scholar 

  22. Nelson SE, Gould MN, Hampton JM, Trentham-Dietz A (2005) A case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer. Breast Cancer Res 7:357–364

    Article  CAS  Google Scholar 

  23. Cox DG, Hankinson SE, Hunter DJ (2005) The erbB2/HER2/neu receptor polymorphism Ile655Val and breast cancer risk. Pharmacogenet Genomics 15:447–450

    Article  PubMed  CAS  Google Scholar 

  24. Vogl FD, Taioli E, Maugard C, Zheng W, Pinto LF et al (2004) Glutathione S-transferases M1, T1, and P1 and breast cancer: a pooled analysis. Cancer Epidemiol Biomarkers Prev 9:1473–1479

    Google Scholar 

  25. Edvardsen H, Kristensen VN, Grenaker Alnaes GI, Bøhn M, Erikstein B et al (2007) Germline glutathione S-transferase variants in breast cancer: relation to diagnosis and cutaneous long-term adverse effects after two fractionation patterns of radiotherapy. Int J Radiat Oncol Biol Phys 67:163–171

    Google Scholar 

  26. Park SK, Yim DS, Yoon KS, Choi IM, Choi JY, Yoo KY et al (2004) Combined effect of GSTM1, GSTT1, and COMT genotypes in individual breast cancer risk. Breast Cancer Res Treat 88:55–62

    Article  PubMed  CAS  Google Scholar 

  27. Steck SE, Gaudet MM, Britton JA, Teitelbaum SL, Terry MB et al (2007) Interactions among GSTM1, GSTT1 and GSTP1 polymorphisms, cruciferous vegetable intake and breast cancer risk. Carcinogenesis 128:1954–1959

    Article  CAS  Google Scholar 

  28. Spurdle AB, Chang JH, Byrnes GB, Chen X, Dite GS et al (2007) A systematic approach to analyzing gene-gene interactions: polymorphisms at the microsomal epoxide hydrolase EPHX and glutathione S-transferase GSTM1, GSTT1, and GSTP1 loci and breast cancer risk. Cancer Epidemiol Biomarkers Prev 16:769–774

    Article  PubMed  CAS  Google Scholar 

  29. Andreassen CN, Alsner J, Overgaard J, Herskind C, Haviland J et al (2005) TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. Radiother Oncol 75:18–21

    Article  PubMed  CAS  Google Scholar 

  30. DeMichele A, Aplenc R, Botbyl J, Colligan T, Wray L et al (2005) Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort. J Clin Oncol 23:5552–5559

    Article  PubMed  CAS  Google Scholar 

  31. Yang G, Shu XO, Ruan ZX, Cai QY, Jin F et al (2005) Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma. Cancer 103:52–58

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We would like to thank the Chennai Willingdon Corporate Foundation for providing financial support for this project. We also thank the patients and subjects who participated as controls, in the study.

Author information

Authors and Affiliations

  1. Department of Molecular Oncology, Cancer Institute (WIA), Adyar, Chennai, 600020, India

    Thangarajan Rajkumar, Mani Samson & Nirmala K. Nancy

  2. Department of Epidemiology and Tumour Registry, Cancer Institute (WIA), Adyar, Chennai, 600020, India

    Ranganathan Rama & Rajaraman Swaminathan

  3. Department of Surgical Oncology, Cancer Institute (WIA), Adyar, Chennai, 600020, India

    Veluswami Sridevi

  4. Department of Pathology, Cancer Institute (WIA), Adyar, Chennai, 600020, India

    Urmila Mahji

Authors
  1. Thangarajan Rajkumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mani Samson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ranganathan Rama
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Veluswami Sridevi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Urmila Mahji
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rajaraman Swaminathan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nirmala K. Nancy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thangarajan Rajkumar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rajkumar, T., Samson, M., Rama, R. et al. TGFβ1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFβ1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo-radiotherapy. Breast Cancer Res Treat 112, 81–87 (2008). https://doi.org/10.1007/s10549-007-9821-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-007-9821-3

Keywords

Search

Navigation